FUNGIZONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNGIZONE is an oral suspension antifungal agent approved by Bristol Myers Squibb in 1971. The drug's specific mechanism of action and indication profile are not publicly detailed in available data. It represents a legacy small-molecule antifungal product with a long commercial history.
LOE Approaching
As LOE approaches, commercial team size is likely contracting; career opportunities are limited to maintenance and transition planning roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FUNGIZONE offers minimal career growth potential due to its LOE-approaching status and legacy market position. Roles available are primarily maintenance-focused, supporting declining sales and managed portfolio transition.
Brand Manager (Legacy Product)Field Sales Representative
Worked on FUNGIZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.